RE: Article on todays RNS13 Mar 2018 21:32
Certainly feels like its our time sooner rather than later !
Phase 1/2 SRA737 Monotherapy Trial (SRA737-01)
Phase 1/2 SRA737 plus Low Dose Gemcitabine Combination Trial (SRA737-02): Trial Update and Expansion Plans
SRA737 PARP inhibitor Combination Programme (SRA737-03)
SRA737 Combination with Immuno-Oncology (SRA737-04)
Tyrosine Kinase 2 (TYK2) inhibitors - distinct molecules moving into candidate selection
Aurora+FLT3 inhibitors - in preclinical development